Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098228 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 686
- Enrollment target
NCT00098228 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 686 participants.
The verdict
NCT00098228, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 686 participants
- Enrollment target
Study Summary
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Interventions
- DRUG QAB149
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2004-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098228
The ClinicalTrials.gov registry entry for NCT00098228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 686 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QAB149 is the first listed.
NCT00098228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098228 about?
NCT00098228 is a clinical study titled "Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
What is the current status of trial NCT00098228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 686 participants. The study started on 2004-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00098228?
The interventions under investigation include: QAB149 (DRUG).
Who is sponsoring clinical trial NCT00098228?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.